In the IQVIA™ LRx database, patients prescribed tafamidis 61 mg in Germany displayed high adherence and persistency rates, which suggest good drug tolerability and ease of use.
Keyphrases
- health insurance
- end stage renal disease
- affordable care act
- ejection fraction
- newly diagnosed
- prognostic factors
- case report
- emergency department
- peritoneal dialysis
- healthcare
- electronic health record
- type diabetes
- randomized controlled trial
- clinical trial
- metabolic syndrome
- machine learning
- insulin resistance
- study protocol